TAO Synergies (TAOX) Preferred Stock Liabilities (2020 - 2026)
TAO Synergies' (TAOX) quarterly Preferred Stock Liabilities came in at $3.9 million in Q2 2026, up 763.35% on a YoY basis from $446942.0 in Q2 2025, and up 74.52% quarter-over-quarter from $2.2 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Preferred Stock Liabilities (2020 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Preferred Stock Liabilities for 7 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Preferred Stock Liabilities rose 763.35% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (up 763.35% YoY), and the FY2025 full-year result was $507927.0, down 44.36% from the prior year.
- Preferred Stock Liabilities advanced to $3.9 million in Q2 2026 per TAOX's latest filing, from $2.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $31.5 million in Q1 2023 and bottomed at $314473.0 in Q3 2024.
- Historically, Preferred Stock Liabilities has averaged $5.1 million across 5 years, with a median of $1.3 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Preferred Stock Liabilities tumbled 97.38% in 2024, then surged 763.35% in 2026.
- Over 5 years, Preferred Stock Liabilities stood at $2.7 million in 2022, then tumbled by 54.55% to $1.2 million in 2023, then fell by 26.2% to $912830.0 in 2024, then sank by 44.36% to $507927.0 in 2025, then jumped by 659.69% to $3.9 million in 2026.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $3.9 million, $2.2 million, and $507927.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | - |
| 10 | TAO Synergies | 30.86 Mn | 30.86 Mn | - | 3.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.86 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 507,927.00 |
| Sep 30, 2025 | 603,797.00 |
| Jun 30, 2025 | 446,942.00 |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 912,830.00 |
| Sep 30, 2024 | 314,473.00 |
| Mar 31, 2024 | 823,555.00 |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.69 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 31.46 Mn |
| Dec 31, 2022 | 2.72 Mn |
| Sep 30, 2022 | 26.67 Mn |
| Dec 31, 2021 | 33.53 Mn |
| Dec 31, 2020 | 5.14 Mn |